Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

SAMETA : A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18-130Age 18-130

Kidney<br/>CancersCancer LocationKidney
Cancers

Systemic therapy,Treatment | Urinary systemKidney,Renal cell carcinoma

Trial Overview Read MoreRead more

This trial is comparing three different types and combinations of targeted therapy for the treatment of papillary renal cell carcinoma that has spread locally or to distant locations in the body.
 

This trial is treating patients with Papillary Renal Cell Carcinoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)

Commercial Sponsor

AstraZeneca

Summary

Eligible participants will be randomised in a 2:1:1 ratio to one of the following intervention groups: Group 1- savolitinib (600mg given orally, once daily) plus durvalumab (1500mg given intravenously, every 4 weeks), Group 2 - sunitinib (50mg given orally, once daily for 4 consecutive weeks, followed by a sunitinib-free interval of 2-weeks, every 6 weeks), or Group 4 - durvalumab monotherapy (1500mg given intravenously, every 4 weeks).

Recruiting Hospitals Read MoreRead more

Box Hill Hospital Medical Oncology
Box Hill
Lauren Mitchell
lauren.mitchell@monash.edu
03 9094 9544

Cabrini Education and Research Precinct
Malvern
Micheleine Uhe
muhe@cabrini.com.au
(03) 9508 3481

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next